Preclinical studies showed that SGN-CD123A demonstrated anti-tumor activities against AML cell lines and primary samples from AML patients with or without adverse cytogenetic profiles or FLT3 mutations. This evidence concerns the gene FLT3 and acute myeloid leukemia.